FT showed a significant anticancer effect in multiple myeloma (MM), which may be mainly through reactive oxygen species (ROS) indirectly down-regulating p-JAK1/2, inhibiting the activation of constitutive p-STAT3, and reducing the binding ability of STAT3/5 to DNA and the translocation of p-STAT3/5 to the nucleus (Kim et al., 2018). This evidence concerns the gene JAK1 and plasma cell myeloma.